Regeneron Pharmaceuticals (REGN)

$738.34 +42.92 (6.17%)
Market Cap 73.49B
Revenue (ttm) 14.34B
Net Income (ttm) 4.50B
EPS (ttm) N/A
PE Ratio 17.96
Forward PE 17.97
Profit Margin 31.41%
Debt to Equity Ratio 0.06
Volume 1,451,004
Avg Vol 1,045,440
Day's Range N/A - N/A
Shares Out 105.72M
Stochastic %K 89%
Beta 0.24
Analysts Strong Sell
Price Target $827.43

Company Profile

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascul...

Industry: Biotechnology
Sector: Healthcare
Phone: 914 847 7000
Address:
777 Old Saw Mill River Road, Tarrytown, United States
Whiskeyunderthebed
Whiskeyunderthebed Jul. 30 at 8:15 PM
$REGN WE should go higher than the 52 week high at $821 this quarter
0 · Reply
DidYouReadThis
DidYouReadThis Jul. 30 at 7:50 PM
$OTLK Do you know what a #14d9 is? Do you think there could possibly be one within 2 weeks-20 years? ​$NVS $ABBV $REGN
0 · Reply
Tom2772
Tom2772 Jul. 30 at 7:30 PM
$OTLK $REGN $RHHBY You know what you own 💎 https://youtu.be/4t43-jAeJ6I?si=FAzfFL3tGRdp741N
1 · Reply
Stekli27
Stekli27 Jul. 30 at 6:27 PM
$OTLK $KOD $REGN👁️👁️
0 · Reply
CarryTradePro
CarryTradePro Jul. 30 at 6:06 PM
$REGN SDOT’s gross profit was only $900K on $129M in sales. RMTG’s margins are way healthier.
0 · Reply
Iwannagofast1
Iwannagofast1 Jul. 30 at 5:03 PM
$REGN Sitting pretty wanted some more under $500 bit i guess not. Happy w the 325 shares I hold
0 · Reply
DidYouReadThis
DidYouReadThis Jul. 30 at 4:26 PM
$REGN I like $REGN #earnings!
0 · Reply
EarningsInsider
EarningsInsider Jul. 30 at 2:02 PM
https://www.marketbeat.com/earnings/reports/2026-7-30-regeneron-pharmaceuticals-inc-stock/ $REGN Regeneron Pharmaceuticals Earnings Transc
0 · Reply
Dragan7
Dragan7 Jul. 30 at 12:50 PM
$REGN Why this drop in pr-market? Shorts?
1 · Reply
JasonCO
JasonCO Jul. 30 at 11:19 AM
$ENPH $QQQ $REGN $SPY Blocked
0 · Reply
Latest News on REGN
Regeneron Pharmaceuticals Earnings Call Transcript: Q2 2026

Jul 30, 2026, 8:30 AM EDT - 8 hours ago

Regeneron Pharmaceuticals Earnings Call Transcript: Q2 2026

Regeneron Pharmaceuticals Earnings release: Q2 2026

Jul 30, 2026, 8:30 AM EDT - 8 hours ago

Regeneron Pharmaceuticals Earnings release: Q2 2026

Regeneron Pharmaceuticals Quarterly report: Q2 2026

Jul 30, 2026, 8:30 AM EDT - 8 hours ago

Regeneron Pharmaceuticals Quarterly report: Q2 2026

Regeneron Pharmaceuticals Slides: Q2 2026

Jul 30, 2026, 8:30 AM EDT - 8 hours ago

Regeneron Pharmaceuticals Slides: Q2 2026

Regeneron cuts FY26 CapEx view to $1.03B-$1.1B from $1.1B-$1.2B

2026-07-30T12:21:28.000Z - 8 hours ago

Regeneron cuts FY26 CapEx view to $1.03B-$1.1B from $1.1B-$1.2B

Regeneron beats quarterly estimates on eczema drug strength, shares rise

Jul 30, 2026, 7:54 AM EDT - 9 hours ago

Regeneron beats quarterly estimates on eczema drug strength, shares rise

Regeneron reports Q2 adjusted EPS $14.29, consensus $10.20

2026-07-30T10:35:57.000Z - 10 hours ago

Regeneron reports Q2 adjusted EPS $14.29, consensus $10.20

Regeneron Reports Second Quarter 2026 Financial and Operating Results

Jul 30, 2026, 6:30 AM EDT - 10 hours ago

Regeneron Reports Second Quarter 2026 Financial and Operating Results

REGN Stockholders Have Rights – If You Lost Money Investing in Regeneron Pharmaceuticals, Inc. Contact Robbins LLP for Information About Recovering Your Losses

Jul 29, 2026, 10:27 PM EDT - 18 hours ago

REGN Stockholders Have Rights – If You Lost Money Investing in Regeneron Pharmaceuticals, Inc. Contact Robbins LLP for Information About Recovering Your Losses

The Scientist With 1,000 Patents Fueling a Drug Powerhouse

Jul 24, 2026, 1:40 PM EDT - 6 days ago

The Scientist With 1,000 Patents Fueling a Drug Powerhouse

$REGN Fraud Notification: Regeneron Sued for Fraud Over Misrepresentations about its Clinical Trials – Investors Notified to Contact BFA Law

Jul 24, 2026, 6:36 AM EDT - 6 days ago

$REGN Fraud Notification: Regeneron Sued for Fraud Over Misrepresentations about its Clinical Trials – Investors Notified to Contact BFA Law

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN

Jul 23, 2026, 10:09 AM EDT - 7 days ago

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN

REGN Breaking News: Regeneron Inc. Sued for Securities Fraud after Revealing Failed Phase III Clinical Trial Resulting in 10% Stock Drop – Investors Notified to Contact BFA Law

Jul 21, 2026, 4:03 PM EDT - 9 days ago

REGN Breaking News: Regeneron Inc. Sued for Securities Fraud after Revealing Failed Phase III Clinical Trial Resulting in 10% Stock Drop – Investors Notified to Contact BFA Law

Regeneron price target raised to $1,000 from $995 at Guggenheim

2026-07-21T12:06:20.000Z - 9 days ago

Regeneron price target raised to $1,000 from $995 at Guggenheim

REGENERNON PHARMACEUTICALS, INC. (REGN) INVESTOR ALERT Investors With Large Losses in Regeneron Pharmaceuticals, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Jul 20, 2026, 2:42 PM EDT - 10 days ago

REGENERNON PHARMACEUTICALS, INC. (REGN) INVESTOR ALERT Investors With Large Losses in Regeneron Pharmaceuticals, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Biohaven enters into clinical supply agreement with Regeneron

2026-07-20T11:35:36.000Z - 10 days ago

Biohaven enters into clinical supply agreement with Regeneron

BHVN

Booking, Alphabet, and 7 Other Stocks to Buy Ahead of Earnings

Jul 15, 2026, 1:20 PM EDT - 15 days ago

Booking, Alphabet, and 7 Other Stocks to Buy Ahead of Earnings

BKNG GOOG GOOGL PAYC PAYX SYK EVR

Regeneron’s dupilumab granted orphan drug designation

2026-07-14T21:05:12.000Z - 16 days ago

Regeneron’s dupilumab granted orphan drug designation

Regeneron price target lowered to $856 from $860 at BofA

2026-07-13T11:21:03.000Z - 17 days ago

Regeneron price target lowered to $856 from $860 at BofA

Regeneron price target lowered to $854 from $855 at Piper Sandler

2026-07-09T11:15:17.000Z - 21 days ago

Regeneron price target lowered to $854 from $855 at Piper Sandler

Regeneron price target lowered to $730 from $788 at Morgan Stanley

2026-07-08T11:40:11.000Z - 22 days ago

Regeneron price target lowered to $730 from $788 at Morgan Stanley

Regeneron price target lowered to $769 from $778 at Truist

2026-07-07T13:16:18.000Z - 23 days ago

Regeneron price target lowered to $769 from $778 at Truist

Regeneron price target lowered to $696 from $707 at RBC Capital

2026-07-07T11:31:19.000Z - 23 days ago

Regeneron price target lowered to $696 from $707 at RBC Capital

Regeneron price target lowered to $800 from $990 at HSBC

2026-07-06T14:30:37.000Z - 24 days ago

Regeneron price target lowered to $800 from $990 at HSBC

Regeneron price target lowered to $750 from $785 at Cantor Fitzgerald

2026-07-06T11:10:40.000Z - 24 days ago

Regeneron price target lowered to $750 from $785 at Cantor Fitzgerald

FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports

Jun 29, 2026, 3:03 PM EDT - 4 weeks ago

FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports

LLY

Eli Lilly, Regeneron among first selections for FDA PreCheck program, CNBC says

2026-06-29T19:00:12.000Z - 4 weeks ago

Eli Lilly, Regeneron among first selections for FDA PreCheck program, CNBC says

AMRX LLY

Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities

Jun 29, 2026, 2:50 PM EDT - 4 weeks ago

Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities

LLY

Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast

Jun 25, 2026, 4:05 PM EDT - 5 weeks ago

Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast

Apogee acquisition is ‘net negative’ for Regeneron, says RBC Capital

2026-06-22T12:24:03.000Z - 5 weeks ago

Apogee acquisition is ‘net negative’ for Regeneron, says RBC Capital

ABBV APGE

Regeneron announces FDA, EMA accept cemdisiran submissions for review

2026-06-22T11:21:00.000Z - 5 weeks ago

Regeneron announces FDA, EMA accept cemdisiran submissions for review

Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)

Jun 22, 2026, 7:00 AM EDT - 5 weeks ago

Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)

Regeneron Pharmaceuticals Transcript: AGM 2026

Jun 12, 2026, 10:30 AM EDT - 6 weeks ago

Regeneron Pharmaceuticals Transcript: AGM 2026

Regeneron Pharmaceuticals Slides: FY 2026

Jun 12, 2026, 10:30 AM EDT - 6 weeks ago

Regeneron Pharmaceuticals Slides: FY 2026

Regeneron Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 2:00 PM EDT - 7 weeks ago

Regeneron Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO

Jun 4, 2026, 7:00 AM EDT - 2 months ago

Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO

CytomX Therapeutics expands licensing agreement with Regeneron

2026-06-03T13:28:50.000Z - 2 months ago

CytomX Therapeutics expands licensing agreement with Regeneron

CTMX

Regeneron's Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak

May 28, 2026, 4:00 PM EDT - 2 months ago

Regeneron's Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak

Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Regeneron Pharmaceuticals, Inc. (REGN)

May 25, 2026, 11:31 AM EDT - 2 months ago

Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Regeneron Pharmaceuticals, Inc. (REGN)

Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss

May 22, 2026, 7:00 AM EDT - 2 months ago

Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss

Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis

May 21, 2026, 5:01 PM EDT - 2 months ago

Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis

Regeneron stock drops double digits on oncology trial failure

May 18, 2026, 3:25 PM EDT - 2 months ago

Regeneron stock drops double digits on oncology trial failure

Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck's Keytruda

May 18, 2026, 7:28 AM EDT - 2 months ago

Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck's Keytruda

Regeneron Shares Slide Premarket after Melanoma Drug Trial Disappoints

May 18, 2026, 7:04 AM EDT - 2 months ago

Regeneron Shares Slide Premarket after Melanoma Drug Trial Disappoints

Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas

May 18, 2026, 7:00 AM EDT - 2 months ago

Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas

Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas

May 18, 2026, 7:00 AM EDT - 2 months ago

Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas

Regeneron drops after skin cancer treatment misses late-stage trial goal

May 18, 2026, 5:57 AM EDT - 2 months ago

Regeneron drops after skin cancer treatment misses late-stage trial goal

Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma

May 15, 2026, 8:19 PM EDT - 2 months ago

Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma

UPDATE – Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair

May 15, 2026, 5:56 PM EDT - 2 months ago

UPDATE – Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair

Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair

May 15, 2026, 4:27 PM EDT - 2 months ago

Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair

Regeneron Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 1:00 PM EDT - 2 months ago

Regeneron Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026

Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years

May 8, 2026, 7:00 AM EDT - 2 months ago

Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years

Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial

May 5, 2026, 7:00 AM EDT - 3 months ago

Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial

Regeneron Pharmaceuticals Earnings Call Transcript: Q1 2026

Apr 29, 2026, 8:30 AM EDT - 3 months ago

Regeneron Pharmaceuticals Earnings Call Transcript: Q1 2026

Regeneron Pharmaceuticals Earnings release: Q1 2026

Apr 29, 2026, 8:30 AM EDT - 3 months ago

Regeneron Pharmaceuticals Earnings release: Q1 2026

Regeneron Pharmaceuticals Quarterly report: Q1 2026

Apr 29, 2026, 8:30 AM EDT - 3 months ago

Regeneron Pharmaceuticals Quarterly report: Q1 2026

Regeneron Pharmaceuticals Slides: Q1 2026

Apr 29, 2026, 8:30 AM EDT - 3 months ago

Regeneron Pharmaceuticals Slides: Q1 2026

Regeneron beats quarterly results estimates on strong Dupixent demand

Apr 29, 2026, 7:43 AM EDT - 3 months ago

Regeneron beats quarterly results estimates on strong Dupixent demand

Regeneron Reports First Quarter 2026 Financial and Operating Results

Apr 29, 2026, 6:30 AM EDT - 3 months ago

Regeneron Reports First Quarter 2026 Financial and Operating Results

Regeneron weighs overseas price for Otarmeni, gene therapy for rare type of hearing loss

Apr 24, 2026, 2:37 PM EDT - 3 months ago

Regeneron weighs overseas price for Otarmeni, gene therapy for rare type of hearing loss

Regeneron CEO on deal with Trump admin to lower drug prices

Apr 24, 2026, 10:30 AM EDT - 3 months ago

Regeneron CEO on deal with Trump admin to lower drug prices

Regeneron Pharmaceuticals Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 3 months ago

Regeneron Pharmaceuticals Proxy statement: Proxy filing

Regeneron Pharmaceuticals Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 3 months ago

Regeneron Pharmaceuticals Proxy statement: Proxy filing

Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.

Apr 23, 2026, 3:46 PM EDT - 3 months ago

Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.

Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free

Apr 23, 2026, 3:40 PM EDT - 3 months ago

Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free

Regeneron to offer prescriptions at most favored nation prices, Trump says

Apr 23, 2026, 3:21 PM EDT - 3 months ago

Regeneron to offer prescriptions at most favored nation prices, Trump says

FDA Approves First-Ever Gene Therapy to Restore Hearing

Apr 23, 2026, 1:42 PM EDT - 3 months ago

FDA Approves First-Ever Gene Therapy to Restore Hearing

Whiskeyunderthebed
Whiskeyunderthebed Jul. 30 at 8:15 PM
$REGN WE should go higher than the 52 week high at $821 this quarter
0 · Reply
DidYouReadThis
DidYouReadThis Jul. 30 at 7:50 PM
$OTLK Do you know what a #14d9 is? Do you think there could possibly be one within 2 weeks-20 years? ​$NVS $ABBV $REGN
0 · Reply
Tom2772
Tom2772 Jul. 30 at 7:30 PM
$OTLK $REGN $RHHBY You know what you own 💎 https://youtu.be/4t43-jAeJ6I?si=FAzfFL3tGRdp741N
1 · Reply
Stekli27
Stekli27 Jul. 30 at 6:27 PM
$OTLK $KOD $REGN👁️👁️
0 · Reply
CarryTradePro
CarryTradePro Jul. 30 at 6:06 PM
$REGN SDOT’s gross profit was only $900K on $129M in sales. RMTG’s margins are way healthier.
0 · Reply
Iwannagofast1
Iwannagofast1 Jul. 30 at 5:03 PM
$REGN Sitting pretty wanted some more under $500 bit i guess not. Happy w the 325 shares I hold
0 · Reply
DidYouReadThis
DidYouReadThis Jul. 30 at 4:26 PM
$REGN I like $REGN #earnings!
0 · Reply
EarningsInsider
EarningsInsider Jul. 30 at 2:02 PM
https://www.marketbeat.com/earnings/reports/2026-7-30-regeneron-pharmaceuticals-inc-stock/ $REGN Regeneron Pharmaceuticals Earnings Transc
0 · Reply
Dragan7
Dragan7 Jul. 30 at 12:50 PM
$REGN Why this drop in pr-market? Shorts?
1 · Reply
JasonCO
JasonCO Jul. 30 at 11:19 AM
$ENPH $QQQ $REGN $SPY Blocked
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Jul. 30 at 10:54 AM
$REGN Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $12.62 down -4.68% YoY • Reported revenue of $4.29B up 16.73% YoY
0 · Reply
Tom2772
Tom2772 Jul. 30 at 8:25 AM
$OTLK $REGN $RHHBY Actions speak louder than words. On July 29, Chairman Faisal G. Sukhtian bought 95,398 shares on the open market for nearly $100,000, increasing his direct holdings to 220,972 shares. I like seeing insiders buying after FDA approval, not selling.
0 · Reply
Synaptric
Synaptric Jul. 29 at 7:55 PM
Infrastructure and drugs getting the attention in contrast to energy losing it for names reporting earnings Thursday morning. Quanta $PWR and Regeneron $REGN climbing to mid-60s. Similar for $BMY . Energy is the opposite story: Valero $VLO reached 80-ish but quickly retreated to a neutral 51. $SHEL near 50 too.
0 · Reply
27R
27R Jul. 29 at 7:26 PM
$REGN Buckle up — earnings before the open tomorrow.
0 · Reply
Maxwell_Osgood
Maxwell_Osgood Jul. 28 at 11:12 PM
$REGN Good boy!
0 · Reply
ScanStock
ScanStock Jul. 28 at 11:06 PM
Big bulls calling you APUS right now for a run! Looks like they might be right, Loads of bulls moving to APUS now! The next low float stock to squeeze north Look APUS starting to run with fresh news <-- $SPY $QQQ $REGN $ENPH ddd
0 · Reply
focafoca99
focafoca99 Jul. 28 at 10:51 AM
$REGN is facing a securities-fraud class action with a September 14 lead-plaintiff deadline.
0 · Reply
Tom2772
Tom2772 Jul. 28 at 4:10 AM
$OTLK $REGN $AMGN BTIG upgraded the stock to ‘Buy’ from ‘Neutral’ and set a price target of $4, a 247% upside potential from current levels. Outlook Therapeutics has moved past regulatory uncertainty and is now focused on commercial execution, BTIG said, according to The Fly. https://stocktwits.com/news-articles/markets/equity/otlk-stock-falls-retail-says-buy-the-dip-btig-upgrade/cZZxFjvR76V $4 and buy sounds good!
2 · Reply
Tom2772
Tom2772 Jul. 27 at 7:32 PM
$OTLK $REGN $ABBV There may be more going on behind the scenes than we know. $OTLK could still be a diamond 💎 in the rough. We may find out soon.
0 · Reply
DidYouReadThis
DidYouReadThis Jul. 27 at 6:31 PM
How many quarters old is $OTLK? How many quarters old was $REGN when it became profitable? Could there possibly be any kind of correlation or 0 correlation?
0 · Reply